Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Jan 8.
Published in final edited form as: Med Phys. 2025 Sep;52(9):e18032. doi: 10.1002/mp.18032

Development and application of a novel tumor habitat analysis technique based on dynamical modeling

Jack B Stevens 1, Jihyeon Je 2, Breylon A Riley 1, Yvonne M Mowery 3,4,5, David M Brizel 3,4, Jian-Guo Liu 6,7, Chunhao Wang 1,3, Kyle J Lafata 1,2,3,6,8
PMCID: PMC12777982  NIHMSID: NIHMS2118894  PMID: 40841341

Abstract

Background:

Oropharyngeal cancer (OPC) exhibits varying responses to chemoradiation therapy, making treatment outcome prediction challenging. Traditional imaging-based methods often fail to capture the spatial heterogeneity within tumors, which influences treatment resistance and disease progression. Advances in modeling techniques allow for more nuanced analysis of this heterogeneity, identifying distinct tumor regions, or habitats, that drive patient outcomes.

Purpose:

To interrogate the association between treatment-induced changes in spatial heterogeneity and chemoradiation resistance of oropharyngeal cancer (OPC) based on a novel tumor habitat analysis.

Methods:

A mathematical model was used to estimate tumor time dynamics of patients with OPC based on the applied analysis of partial differential equations. The position and momentum of each voxel was propagated according to Fokker-Planck dynamics, i.e., a common model in statistical mechanics. The boundary conditions of the Fokker-Planck equation were solved based on pre- and intra-treatment (i.e., after 2 weeks of therapy) 18F-FDG-PET SUV images of patients (n=56) undergoing definitive (chemo)radiation for OPC as part of a previously conducted prospective clinical trial. Tumor-specific time dynamics, measured based on the solution of the Fokker-Planck equation, were generated for each patient. Tumor habitats (i.e., non-overlapping subregions of the primary tumor) were identified by measuring vector similarity in voxel-level time dynamics through a fuzzy c-means clustering algorithm. The robustness of our habitat construction method was quantified using a mean silhouette metric to measure intra-habitat variability. Fifty-four habitat-specific radiomic texture features were extracted from pre-treatment SUV images and normalized by habitat volume. Univariate Kaplan-Meier analyses were implemented as a feature selection method, where statistically significant features (p<0.05, log-rank) were used to construct a multivariate Cox proportional-hazards model. Parameters from the resulting Cox model were then used to construct a risk score for each patient, based on habitat-specific radiomic expression. The patient cohort was stratified by median risk score value and association with recurrence-free survival (RFS) was evaluated via log-rank tests.

Results:

Dynamic tumor habitat analysis partitioned the gross disease of each patient into three spatial subregions. Voxels within each habitat suggested differential response rates in different compartments of the tumor. The minimum mean silhouette value was 0.57 and maximum mean silhouette value was 0.8, where values above 0.7 indicated strong intra-habitat consistency and values between 0.5 and 0.7 indicated reasonable intra-habitat consistency. Nine radiomic texture features (three GLRLM, two GLCOM, and three GLSZM) and SUVmax were found to be prognostically significant and were used to build the multivariate Cox model. The resulting risk score was associated with RFS (p=0.032). By contrast, potential confounding factors (primary tumor volume and mean SUV) were not significantly associated with RFS (p=0.286 and p=0.231, respectively).

Conclusion:

We interrogated spatial heterogeneity of oropharyngeal tumors through the application of a novel algorithm to identify spatial habitats on SUV images. Our habitat construction technique was shown to be robust and habitat-specific feature spaces revealed distinct underlying radiomic expression patterns. Radiomic features were extracted from dynamic habitats and used to build a risk score which demonstrated prognostic value.

1. Introduction

Oropharyngeal cancers (OPC) are a major contributor to the number of overall cancer diagnoses and deaths in the United States1. Whilst therapeutic strategies for the treatment of OPC are multimodal, including surgery and/or neoadjuvant chemoradiation, normal tissue toxicities remain a key challenge and often negatively impact quality of life2. Adaptive therapy has emerged as a promising technique, whereby dose and/or treatment volumes are modified throughout the course of therapy, for example deintensification3 of dose for early responding HPV-positive OPC tumors46. Imaging may provide important prognostic information that can guide adaptive therapies. For example, 18F-FDG PET images can quantify the underlying metabolic properties of OPC tumors79 as a surrogate biomarker of adaptive intervention. Recent work has also suggested that intra-treatment 18F-FDG-PET imaging, where patients are additionally imaged during the chemoradiation regiment, may provide further prognostic information to guide adaptive therapy10,11.

Spatial heterogeneity of tumor metabolism measured with 18F-FDG-PET has been identified as an important feature associated with patient outcomes1216. Prior work has suggested that heterogeneity in tumor metabolism is correlated with hypoxic tumor sub-regions17, which has been further investigated using targeted hypoxia radiotracers14,18,19. Spatial heterogeneity in OPC tumors is primarily characterized either by aggregate metrics, such as maximum standardised uptake value (SUVmax), or high-throughput computational techniques, such as radiomics. Tumor SUVmax has been extensively studied as a potential prognostic biomarker and has been linked to poor patient outcomes11,2025. However, recent studies argue that reducing complex tumor biology to a single number is an oversimplification26 and that the association between SUV-based parameters and patient outcomes is not robust27,28. As a result, high-throughput radiomic techniques have increasingly been applied to derive more complex features that could be used to adapt treatment strategies. For example, pre-treatment 18F-FDG-PET radiomics have been used to predict clinically relevant endpoints for OPC, such as locoregional recurrence29, overall survival30, and normal tissue toxicities31. Still, the scientific results of these studies have been mixed, with some highlighting predictive value3234 and others finding no such value10,35.

Data assimilation of radiomic expression with deterministic, mathematical models may enhance the fidelity of purely data-driven radiomics research10,3639. These models often address key limitations in quantitative imaging research and offer the potential for deeper and more nuanced analysis of radiomic feature expression. For example, novel clustering algorithms (based on mathematical models commonly used in statistical mechanics) have been developed to partition OPC patients based only on 18F-FDG-PET radiomic expression patterns37. Likewise, deterministic models have also been used to link the biological effect of radiation dose to deep learning outcome predictions for OPC patients36. Finally, these approaches also add utility to study time interval analyses, i.e., characterization of image time evolution to interrogate the progression of disease between different timepoints38. Collectively, these approaches can quantify changes in spatial heterogeneity of tumors during treatment by modeling the time dynamics of the tumor and incorporating that information into the radiomic analysis.

In this work, we propose a novel approach to construct spatial tumor habitats based on the time evolution of metabolic uptake measured on 18F-FDG-PET SUV images of OPC patients. While previous studies rely on image thresholding or static clustering methods to create spatial tumor habitats15,16,4045, our habitat approach incorporates time dynamics into the problem, allowing for a more detailed characterisation of underlying spatial heterogeneity in response to treatment. Our implementation is based on an underlying mathematical framework to model tumor-specific time dynamics parameterized by clinical PET images. We use a fuzzy clustering algorithm to construct spatial-temporal habitats and demonstrate that habitat-specific radiomic features are associated with patient outcomes. Interrogation of underlying spatial-temporal heterogeneity in oropharyngeal tumors will likely enable robust and biologically informed studies that connect the disease phenotype to patient outcomes.

2. Methods

2.1. Patients, treatment, and image acquisition

We developed and evaluated our dynamic tumor habitat approach based on patients enrolled on a prospective, single-institution clinical trial (NCT01908504) conducted at Duke University Medical Center11. Specifically, we considered patients that underwent curative radiotherapy for oropharyngeal cancer (OPC). Patients were prescribed a course of intensity-modulated radiation therapy (IMRT) according to standard clinical practice, and the majority received concurrent chemotherapy. The dose prescription was either 70 Gy in 35 fractions, or 67.5 Gy in 30 fractions, with the sequential boost strategy. Fifty-six patients with confirmed OPC were studied. All patients had known primary disease, no prior surgical removal or resection of the primary tumor, no prior chemotherapy, and single primary tumors. Follow-up included fiberoptic laryngoscopy, additional imaging as needed, and biopsies of suspicious lesions. Recurrence-free survival (RFS) was the primary clinical endpoint and defined as the time from conclusion of radiation treatment to disease recurrence. Patients lost to follow-up were censored at the last date of follow-up. The full patient characteristics are shown in supplemental table 1.

Each patient received two 18F-FDG-PET/CT scans, one prior to radiation treatment and one intra-treatment, i.e., after 2 weeks (20 Gy) of therapy. Scanner type, imaging protocols, and acquisition parameters were consistent across all patients. Primary gross tumor segmentation was performed by a radiation oncologist on CT images and subsequently transferred to the PET images. Images were interpolated to an isotropic resolution of 1.17 mm and re-sampled based on IBSI recommendations46. Image registration and verification were performed according to a previously published technique39. Tumor staging was conducted according to the AJCC 8th edition47.

2.2. Dynamic habitat construction

Figure 1 shows an overview of our methodology, where tumor habitats are identified as unique solutions to the Fokker-Planck equation given pre-treatment and intra-treatment imaging as boundary conditions. Each habitat represents similarity in modeling dynamics for a set of clustered voxels within the tumor. Intra-habitat differences (i.e., 1, 2, 3) represent contrastive dynamics of tumor metabolism during treatment.

Figure 1:

Figure 1:

Habitat construction methodology. Temporally registered PET images were input into a Fokker-Planck based algorithm which generated mathematical representations of the in-between images. The resulting tensor object was used to identify spatial tumor habitats based on metabolic expression of tumors during treatment.

2.2.1. High-dimensional image analysis via Fokker-Planck dynamics

We hypothesized that the time evolution between pre- and intra-treatment PET imaging could be modeled as a continuous process which obeys canonical laws of mathematics. To test this hypothesis, a previously developed method based on Fokker-Planck dynamics48 was used to construct high dimensional representations of tumors parameterized by PET imaging. In this approach, which is formally known as an equilibrium-driven deformation49, 18F-FDG-PET SUV images (pre-treatment and intra-treatment) are interpreted as boundary conditions to solve a mathematical representation of the image evolution. The process is commonly known as “inbetweening auto-animation” and is based on techniques from statistical mechanics. Mathematically, the time evolution of gray-level intensities within an image volume is modeled by the Fokker-Planck equation50,

tρ=ρ+ρϕ=·πρπ, (1)

where ρR3 represents the gray-level intensities of the image and πeϕ defines the equilibrium density function (i.e., a Gibbs measure51) which is a stationary solution to equation 1. The variable ϕ is the system Hamiltonian, and by analogy to classical mechanics, can be interpreted as the energy of the system. For our application, we interpret this as the potential force which drives evolution between the pre- and intra-treatment images38. Specifically, the intra-treatment PET image defined an “energy landscape”, i.e., the driver of a potential force that uniquely determined evolution between the initial condition (pre-treatment image) and the equilibrium (intra-treatment image). We argue that this is an appropriate formalism, as the intra-treatment PET image contains extensive information about the disease metabolism in response to (chemo)radiation therapy. Given that the disease phenotype is captured in detail by PET imaging, we argue that the energy landscape derived from the intra-treatment imaging defines a reasonable driving force between the initial (pre-treatment) and equilibrium (intra-treatment) states.

Here, ρ0, which is defined by the pre-treatment SUV image, satisfies the following constraint,

ρ0dx=πdx. (2)

The pre-treatment and intra-treatment images define no-flux boundary conditions of the Fokker-Planck equation (equation 1). This is expressed mathematically by the following equation,

nρπ=0onΩ, (3)

where n defines the normal vector to the boundary surface Ω. Equation 1 was solved numerically using a previously published finite-volume method on structured grids52.

The solution of equation 1 is a 4D tensor (three spatial dimensions and one temporal dimension) that describes the time evolution between the pre- and intra-treatment SUV images. This can be expressed mathematically by the tensor Ψ, where

ΨR4=x,y,z,t|x,y,zR,tR+. (4)

2.2.2. Spatial habitat construction using a fuzzy clustering algorithm

Equations 14 were applied to the PET images of patients on NCT01908504, where Ψ represents the image dynamics of each patient. To identify spatial tumor habitats of Ψ, a fuzzy c-means clustering algorithm was used to partition voxels into separate groups based on local similarity in the time dynamics53. First, N tumor voxel indices were extracted by a simple binary search algorithm applied to the gross tumor contour. The corresponding values of ρ were sorted into vectors xj,

xj=xj1,xj2,xj3,,xjT,1jN (5)

where, T is the number of time points and each vector xj represents the time evolution of a given tumor voxel. Cluster centers were computed by the algorithm and defined by the vectors ci,

ci=ci1,ci2,ci3,,ciT,1iC (6)

where C is the number of clusters. The fuzzy clustering algorithm then assigns membership values for each vector that represents the degree to which that vector belongs to each cluster. This was accomplished by minimizing the following objective function,

Jm=i=1Cj=1Nμijmdij2 (7)

Here, m>1 is an exponent that controls the fuzziness of the clustering algorithm (i.e., the degree of overlap between distinct clusters), μijm is the membership value for the jth vector of the ith cluster (corresponding to a particular exponent m), and dij is the Euclidean distance from the jth vector to the ith cluster,

dij=xj-ci2 (8)

where · is the standard L2 norm. Cluster centers, membership values, and Euclidean distances were iteratively computed until the objective function reached a pre-defined minimum threshold value. Each voxel was then assigned to the cluster with maximum membership value. Tumor habitat masks were created by assigning each voxel within the gross tumor the appropriate cluster index.

As the optimal number of clusters to use in fuzzy clustering algorithms is non-trivial, we calculated a validity index54 and performed fuzzy clustering 10 times, changing the number of clusters from 2 to 11. This procedure was repeated using imaging data from each patient included in the study, which yielded a patient-specific validity index. The optimal number of clusters was defined as the number of clusters which minimized the validity index for each patient. Finally, the overall number of clusters was chosen as the most frequent optimal value across all patients. For our dataset, the optimal number of clusters was determined to be 3.

The selection of the optimal number of timepoints from which to sample the tensor defined by equation 4 required a quantitative evaluation based on habitat-derived metrics. To address this, we constructed habitats for each patient using multiple values of T (from 1 to 50) and characterized differences in the resulting habitats. To identify the optimal value, we used the ratio of habitat volumes as a stability metric. Specifically, we calculated the habitat volumes for each patient (normalized to tumor volume) and took the mean to obtain an aggregate measure of the habitat volume ratios across the entire patient cohort. This process was repeated for different values of T. We then plotted the mean habitat volume of each habitat against T and then calculated the moving variance to determine the minimum value of T such that the mean volume became stable for each habitat.

To quantify the robustness of our habitat construction algorithm, we used a silhouette metric55. The silhouette metric measures both intra-habitat consistency (cohesion) and inter-habitat separability (separation). For a given point i (in this case the value of voxel i), the silhouette metric s is defined as

si=bi-aimaxai,bi. (9)

where, ai is the mean distance between i and all other points within the same cluster and bi represents the minimum mean distance between i and points in a different cluster. For each patient, voxel-specific silhouette metrics were calculated and subsequently averaged to quantify the habitat quality with a single number. These mean silhouette metrics were then plotted across patients and an overall metric, known as the silhouette coefficient, was defined,

SC=maxCs-C (10)

where s- is the average of silhouette metrics (equation 9) taken over all patients and C is the number of clusters. The silhouette metric ranges from -1 to 1, with values close to 1 indicating well defined and separated clusters. Silhouette coefficients above 0.7 indicate robust clusters, and silhouette coefficients above 0.5 indicate reasonable clusters56. To ensure self-consistency when comparing habitats across patients, we sorted each habitat in decreasing order by volume.

2.3. Habitat-specific radiomic feature extraction

Radiomic features were extracted from pre-treatment PET images to characterize each tumor habitat. Feature extraction was performed using an externally validated57, IBSI-benchmarked46 radiomics platform58. Images were discretised using a fixed-bin number (FBN) method with 64 gray levels, justified based on prior work59. Habitat specific intensity masks were created through voxel-wise multiplication of each habitat mask (constructed using the method described in section 2.2.2) and the pre-treatment SUV image. This yielded 3 intensity masks for each patient, from which 54 radiomic texture features were extracted. The list of radiomic features extracted is provided in supplemental table 2. To mitigate potential bias introduced by variation in habitat volume60, radiomic features were scaled by a weighting factor W, defined as the normalised habitat volume,

Wi=ViVtotal (11)

where Vi is the volume of the ith tumor habitat for a given patient. The resulting feature space can be mathematically described by the set of matrices

𝓕=F1,F2,F3 (12)

where,

FK=fi,jRm×n (13)

is the radiomic feature space corresponding to the Kth habitat (K=1,2,3), and the coordinates (i,j) represent the ith radiomic feature observed for the jth patient. Each feature vector was normalized to zero-mean and unit variance. To ensure repeatability of radiomic features extracted, we performed a sensitivity analysis by repeating the habitat construction and feature extraction five times. For comparison, the same radiomic features were extracted from the GTV and the peritumoral region, defined as a 3-millimetre-wide annular region enclosing the GTV61.

2.4. Association of habitat-derived radiomic features with clinical outcomes

We implemented a univariate feature selection process to identify potential drivers of prognostic signal. Kaplan-Meier survival curves were calculated for each feature, where the patient cohort was separated into two groups by the median feature value, and log-rank tests were used to assess statistical significance (p<0.05)62. Analysis was conducted using the MATLAB-based survival analysis package MATSURV63.

To calculate the risk score, multivariate Cox proportional hazards models were defined using the features selected above as covariates. Additionally, SUVmax was included as a covariate to show that our method can augment aggregate image-based metrics. Models were built using the MATLAB function coxphfit. We defined the risk score for the jth patient, RSj=i=1Nfijbi, where fij is the ith feature value and bi is the corresponding Cox model coefficient64. The risk score was assessed for prognostic value through Kaplan-Meier analysis, where a log-rank p-value less than 0.05 was statistically significant.

To demonstrate the added utility of our Fokker-Planck algorithm, we compared this risk score with an equivalent derived only from the averaged pre- and intra-treatment images. Furthermore, we compared our radiomic features extracted from the dynamic habitats with benchmark features extracted from the GTV and peritumoral region.

3. Results

3.1. Dynamic tumor habitat analysis

3.1.1. Tumor habitat visualisation

Implementation of the habitat construction methodology outlined in section 2.2 yielded patient specific dynamic tumor habitats (figure 2). Tumor habitats varied in phenotype among patients based on differences in image time dynamics according to the Fokker-Planck algorithm. As shown in figures 2 and 3, tumor habitats qualitatively reflected spatial sub-compartments of disease.

Figure 2:

Figure 2:

Visualisation of tumor habitats for six representative patients. (a) Axial slices of PET/CT images illustrating metabolic activity of OPC tumors. (b) Volumetric renderings of the gross tumor volume and the dynamic tumor habitats generated in our study, in decreasing order of habitat volume.

Figure 3:

Figure 3:

(a) Axial visualisation of habitat masks for a representative patient. (b) Image evolution according to the Fokker-Planck equation, separated by tumor habitat, which highlights the heterogenous tumor metabolism throughout the treatment period.

Representative morphology features, averaged across the patient cohort, are shown in table 1.

Table 1:

Average morphology features for each habitat across the patient cohort.

Habitat number Volume [cm3] Surface Area [cm2] Surface-to-volume ratio Compactness 1 Sphericity
1 14.56 83.85 6.89 0.012 0.36
2 10.07 59.15 7.20 0.013 0.39
3 5.79 22.81 5.14 0.032 0.70

3.1.2. Timepoint sampling frequency

Implementation of the parameter selection process described in section 2.2.2 yielded an optimal sampling frequency of 18 in-between timepoints. Figures 4 and 5 show the criteria used to select this value, where stability in the variance of habitat volume ratios (figure 5) was identified as a surrogate for stability in the habitat construction algorithm.

Figure 4:

Figure 4:

Change in mean habitat volume as sampling frequency is increased.

Figure 5:

Figure 5:

Variance in habitat volume calculated using a sliding window to visualise the stability of the algorithm as the timepoint sampling frequency is increased.

The distributions of habitat volumes for individual patients across timepoint sampling frequencies are shown in supplemental figures S.1, S.2, and S.3.

3.1.3. Habitat consistency

Quantification of habitat consistency demonstrated the robustness of our methodology (figure 6). Calculation of silhouette coefficients for each patient (figure 6 (a)) revealed a minimum value of 0.57 and a maximum value of 0.8. Most patients had silhouette coefficients between 0.5 and 0.7, which indicated reasonable intra-habitat consistency. Furthermore, 14 patients had silhouette coefficients above 0.7, suggesting robust tumor habitats. Figure 6 (b) shows illustrating examples of silhouette plots for two patients: one with the lowest intra-habitat consistency, i.e., the least robust habitats; and one with the highest intra-habitat consistency, i.e., the most robust habitats. The silhouette plot groups all voxels within a given habitat and plots the corresponding silhouette metrics (equation 9). The ideal case would be all points equal to 1 for each habitat, i.e., the plot would appear rectangular with each horizontal line having a length of one. The degree to which each group “falls off” indicates the amount of inconsistency in each habitat. Voxels with negative silhouette metrics are the least consistent with the rest of the voxels within a habitat.

Figure 6:

Figure 6:

Quantifying habitat quality. (a) Silhouette coefficient (equation 10) for each patient in the study. The green region represents patients with very consistent tumor habitats, and the yellow region represents patients with consistent tumor habitats. (b) Representative silhouette plots for the patients with the most (SC=0.8) and least (SC=0.57) robust tumor habitats. Silhouette coefficients, i.e., the mean of all silhouette metrics for a given patient, are indicated by the vertical red lines.

3.2. Prognostic value of habitat-derived radiomics

Univariate feature selection performed using Kaplan-Meier survival curves and log-rank tests revealed habitat-specific radiomic features that were associated with recurrence free survival. These statistical parameters and multivariate Cox regression coefficients are summarized in Table 2. Notably, all prognostic features were derived from habitat 3 and included three run-length matrix features65, two co-occurrence matrix features66, and three size-zone matrix features67.

Table 2:

Statistical results from feature selection and Cox proportional hazards model.

Habitat Number Feature family Feature Name Log-rank p-value Hazard Ratio (95% CI) Cox Regression coefficient
3 GLRLM Normalized run-length non-uniformity 0.0073 4.67 (1.75 – 12.5) −0.0397
3 GLRLM Run percentage 0.0085 4.55 (1.71 – 12.1) 1.0590
3 GLRLM Short run emphasis 0.0396 3.05 (1.14 – 8.12) −0.6700
3 GLCOM Sum entropy 0.0396 3.05 (1.14 – 8.12) −0.7774
3 GLCOM Joint entropy 0.0396 3.05 (1.14 – 8.12) 0.7245
3 GLSZM Zone size entropy 0.0048 4.97 (1.86 – 13.3) −0.3984
3 GLSZM Large Zone Emphasis 0.0238 3.36 (1.26 – 8.97) −7.4720
3 GLSZM Zone size variance 0.0238 3.36 (1.26 – 8.97) 7.1658
N/A N/A SUVmax 0.045 2.97 (1.11 – 7.91) −0.8502

Potential confounding surrogates for these features, i.e., mean SUV, and tumor volume, were tested for statistical significance and were not prognostic (p=0.430 and p=0.110, respectively). SUVmax was found to be associated with recurrence-free survival (p=0.045), indicating a potential advantage over other common aggregate metrics (figure 7 (b)). Our radiomic sensitivity analysis revealed no variation in features extracted when the process was independently repeated five times.

Figure 7:

Figure 7:

Prognostic value of the habitat-derived risk score. (a) Kaplan-Meier curve and risk table demonstrating statistically significant separation of the patient group by median risk score value. (b) Kaplan-meier curve and risk table where patients are stratified by median SUV-max, which highlights the potential prognostic benefit of this metric.

Calculation of the patient specific risk score (equation 14) and stratification of the patient cohort by median risk score value allowed for the construction of a Kaplan-Meier survival curve (figure 7 (a)). This survival curve demonstrated statistically significant (p=0.032) separation of patients by median risk score. The equivalent risk score derived from only the pre- and intra-treatment images (i.e., without using the Fokker-Planck algorithm to generate approximate image dynamics) was not associated with recurrence-free survival (p=0.102). Additionally, benchmark features extracted from the GTV and peritumoral region did not yield a prognostic risk score (for further details, see supplemental figures S.6, S.7, and S.8). This highlights the importance of the dynamical aspect of our work.

4. Discussion

In this study, we designed a novel algorithm to construct dynamic tumor habitats based on the application of mathematical models and demonstrated an application of our technique to oropharyngeal cancer. The key innovation in our work is the method of habitat construction based on modeling image dynamics during therapy. Other studies have argued for the importance of habitats to study spatial heterogeneity in oropharyngeal tumors. However, the majority are based on image thresholding approaches, e.g., the Otsu method which maximises the variance between groups of voxels to construct habitats. While these approaches can provide useful information, they can only capture spatial heterogeneity at a particular snapshot in time. Our approach incorporates dynamics directly into habitat construction. The field of study from which the mathematical model originates, i.e., statistical mechanics, focuses on the characterisation of complex physical systems by their macroscopic behaviour. While studying each microscopic component of a system may provide a complete description of its physical behaviour, this quickly becomes intractable when applied to real life problems. The innovation of our work is the application of these traditional physics techniques to solve problems in medicine, realising that the fundamental methods are independent of the specific application. Our results demonstrate new radiomics data that is more specific to different compartments of the disease and based on differences in local tumor response during treatment.

Our dynamic tumor habitat analyses revealed spatial heterogeneity in the evolution of metabolic activity measured on SUV images of patients with OPC. This heterogeneity was characterized using habitat-specific radiomics features, which were then used to construct a prognostic risk score. We showed that separating tumors into sub-regions based on metabolic activity over time can provide useful information when combined with high throughput radiomics techniques. There are a several potential explanations for the prognostic signal that we observed. By separating the gross tumor into spatial subregions, we increased the amount of information that can be used in downstream radiomics analysis. Our habitats may therefore describe the gross disease in finer detail than previously studied methods, such as regions of aerobic disease and/or regions of hypoxic disease14,19,68. Furthermore, given that the mathematical model was defined using both pre- and intra-treatment imaging, dynamic habitats may also reveal information about differential resistance to radiation therapy. Future work will aim to translate the habitats constructed in this study to potential biological phenomena (e.g., hypoxia, immune dysregulation, etc.).

Qualitatively, we observed similar patterns in habitat formation across most of the patient cohort. In 55 of the 56 patients studied, habitat 3 (i.e., the smallest by volume) corresponded to an interior region of the GTV which could represent the tumor core. Furthermore, 46 patients had habitats that were consistent with those shown in Figure 3, i.e., the largest habitat corresponded to the tumor periphery. These observations are particularly intriguing, given that our algorithm was based on an unsupervised clustering approach. Therefore, we hypothesize that there exist some intrinsic similarities between these distinct regions that was captured by our dynamic algorithm. However, as this study was data-driven and conducted with a relatively small sample size, we cannot make broader interpretations of these results. Future work on independent, prospective trial data could confirm the preliminary findings presented in this study.

Some studies have suggested that the central tumor region corresponds to the highest metabolic uptake69, and others have linked regions of greater metabolism with higher radioresistance70,71. Therefore, it is possible that the innermost habitat represents the most aggressive and nonresponsive area of the disease and drives patient outcomes. While these interpretations are currently speculative, characterization of the tumor microenvironment and linking it to patient outcomes is an exciting research frontier.

Numerous prior studies have argued the importance of spatial heterogeneity in the characterization of underlying tumor phenotype across various imaging modalities and disease sites. MRI is often used to define spatial tumor habitats due to the large amount of anatomical/physiological information that can be captured. Bailo, et al.12 investigated spatial heterogeneity, hypoxia, and perfusion in malignant gliomas utilizing diffusion-weighted MRI and PET imaging. Similarly, Jeong, et al.41 investigated the physiology of CNS lymphoma by constructing tumor habitats based on ADC and cerebral blood volume measurements from susceptibility MR imaging. Quantitative MR habitat analyses have also been used to assess treatment response in the tumor microenvironment for breast cancer patients42,45 and to differentiate radionecrosis from disease recurrence43,44. Beyond MR, habitat derived PET/CT radiomics has shown promise in predicting mutation of colorectal cancer16 and survival of patients with high-grade ovarian cancer15. Our work complements these studies and is especially unique due to the longitudinal nature of our data, as we can extend our analyses to the dynamics of the tumor microenvironment.

Prior work has already identified that intratumor heterogeneity can pose a challenge for personalized medicine. Specifically, genomic and molecular biopsy-based assays often represent only small sub-regions of the tumor, as opposed to the entire phenotype72,73. This is further complicated when radiation, which represents a significant perturbation of the underlying biology, is introduced. Indeed, differential rates of cell killing in various subclonal regions of the gross disease could be a contributing factor in the tumor habitats that were observed in this study. Spatial variation in radiosensitivity, which is potentially captured by our tumor habitats, could represent an important aspect of response to radiation therapy. Further work, including incorporation of radiation-induced cell killing, such as the lethal and potentially lethal (LPL) model74, may lead to additional insight on the relationship between spatial tumor habitats and radiation therapy.

In this work, we did not directly encode the effects of radiation dose into our algorithm. Since the dataset that we used was from a prospective trial with a uniform dose prescription regime, we argue that direct modelling of radiation dose was not necessary in this preliminary study. Furthermore, other studies using the same dataset have shown that dosimetry is a shallow feature, and that the most important information can be derived from the PET signal alone36. However, incorporating dose information into our algorithm is a natural extension and prior studies have already shown promising results when incorporating radiation dose into deterministic models, specifically when integrating the result into deep learning frameworks39. In the future, we aim to combine models of radiation dose with patient specific dose distributions to capture heterogeneities that are induced by treatment. Furthermore, we did not include low dimensional clinical features in the multivariate Cox model in this work. These features were not associated with recurrence free survival when tested using univariate or multivariate analyses. However, emerging data-fusion methodologies75 that can integrate low dimensional clinical features with high dimensional radiomics features may enhance the clinical interpretability of future studies.

Our work presents an original method for constructing dynamic tumor habitats, but there are some key limitations that warrant discussion. The main limitation of this study is the lack of an independent dataset for external validation. Our analysis is based on data from a recently completed prospective clinical trial, where intra-treatment PET images were acquired via a standardized, prospectively controlled imaging protocol on a single scanner. This limits immediate external validation, and so the current TRIPOD76 Type 1a study was conducted to demonstrate apparent performance and produce hypothesis generating data. That said, the core impact of this work lies not in the specific clinical findings, but in the development of a generalized algorithmic framework and the introduction of dynamic habitats as a model for spatiotemporal tumor heterogeneity. While c-means clustering involves tuneable parameters that should eventually be evaluated on external data, the solutions to the Fokker-Planck equation are deterministic and patient-specific. Model parameters are therefore not learned from population data, but rather fit individually for each patient, reducing the risk of overfitting and enhancing interpretability. Nevertheless, external validation remains an important future step to maximize scientific value.

Furthermore, our feature selection algorithm used to identify potential drivers of prognostic signal was rudimentary. Given the number of features extracted was much greater than the sample size, a feature selection algorithm was required. Univariate feature selection methods are not unprecedented77, but there are many other possible feature selection algorithms to choose from78, which often rely on splitting the data into separate training and testing sets. However, recent work79 has shown that in the case of small datasets, the particular split into training and testing sets can change the resulting analysis. Given the size of our dataset, we chose a simple univariate feature selection algorithm to avoid these types of issues. In the future, we plan to address this limitation by using a larger dataset and investigating different feature selection algorithms to enhance the robustness of our findings. Larger sample sizes may also allow for more advanced feature selection methods that have already shown promise in radiomics studies, such as principal component analysis (PCA)80. We confirmed that the prognostic signal observed in figure 8 was reflected qualitatively when the sampling frequency was changed (see supplemental figures S.4 and S.5 for examples).

5. Conclusion

Qualitative differences in habitat morphology suggested connections between habitats and response to therapy, such as tumor shrinkage. Key parameters, such as timepoint sampling frequency and optimal number of clusters were quantitatively derived from the patient dataset. The derived patient-specific risk score demonstrated prominent patient outcome prognostic value in multivariate analysis. Our study provides a preliminary approach to a more nuanced understanding of tumor heterogeneity, with potential implications for patient-specific precision oncology.

Supplementary Material

Supplemental material

Footnotes

Conflict of interest statement

The authors have no conflicts of interest to declare.

Data availability statement

Research data are stored in an institutional repository and deidentified data will be shared upon request to the corresponding author through a data use agreement.

References

  • 1.Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. Jan 2023;73(1):17–48. doi: 10.3322/caac.21763 [DOI] [PubMed] [Google Scholar]
  • 2.Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. Sep 10 2007;25(26):4096–103. doi: 10.1200/JCO.2007.13.3983 [DOI] [PubMed] [Google Scholar]
  • 3.Adelstein DJ, Ismaila N, Ku JA, et al. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. Jun 20 2019;37(18):1578–1589. doi: 10.1200/JCO.19.00441 [DOI] [PubMed] [Google Scholar]
  • 4.Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. Nov 10 2011;29(32):4294–301. doi: 10.1200/JCO.2011.36.4596 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.O’Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. Apr 2016;17(4):440–451. doi: 10.1016/S1470-2045(15)00560-4 [DOI] [PubMed] [Google Scholar]
  • 6.Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. Jul 1 2010;363(1):24–35. doi: 10.1056/NEJMoa0912217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Brizel DM. Head and neck cancer as a model for advances in imaging prognosis, early assessment, and posttherapy evaluation. Cancer J. May-Jun 2011;17(3):159–65. doi: 10.1097/PPO.0b013e31821e8a09 [DOI] [PubMed] [Google Scholar]
  • 8.Goel R, Moore W, Sumer B, Khan S, Sher D, Subramaniam RM. Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. AJR Am J Roentgenol. Aug 2017;209(2):289–303. doi: 10.2214/AJR.17.18301 [DOI] [PubMed] [Google Scholar]
  • 9.Sjovall J, Chua B, Pryor D, et al. Long-term results of positron emission tomography-directed management of the neck in node-positive head and neck cancer after organ preservation therapy. Oral Oncol. Mar 2015;51(3):260–6. doi: 10.1016/j.oraloncology.2014.12.009 [DOI] [PubMed] [Google Scholar]
  • 10.Lafata KJ, Chang Y, Wang C, et al. Intrinsic radiomic expression patterns after 20 Gy demonstrate early metabolic response of oropharyngeal cancers. Med Phys. Jul 2021;48(7):3767–3777. doi: 10.1002/mp.14926 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Mowery YM, Vergalasova I, Rushing CN, et al. Early (18)F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence. Int J Radiat Oncol Biol Phys. Nov 15 2020;108(4):969–976. doi: 10.1016/j.ijrobp.2020.08.029 [DOI] [PubMed] [Google Scholar]
  • 12.Bailo M, Pecco N, Callea M, et al. Decoding the Heterogeneity of Malignant Gliomas by PET and MRI for Spatial Habitat Analysis of Hypoxia, Perfusion, and Diffusion Imaging: A Preliminary Study. Front Neurosci. 2022;16:885291. doi: 10.3389/fnins.2022.885291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.O’Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res. Jan 15 2015;21(2):249–57. doi: 10.1158/1078-0432.CCR-14-0990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. Mar 2014;55(3):414–22. doi: 10.2967/jnumed.113.129858 [DOI] [PubMed] [Google Scholar]
  • 15.Wang X, Xu C, Grzegorzek M, Sun H. Habitat radiomics analysis of pet/ct imaging in high-grade serous ovarian cancer: Application to Ki-67 status and progression-free survival. Front Physiol. 2022;13:948767. doi: 10.3389/fphys.2022.948767 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhao H, Su Y, Wang Y, et al. Using tumor habitat-derived radiomic analysis during pretreatment (18)F-FDG PET for predicting KRAS/NRAS/BRAF mutations in colorectal cancer. Cancer Imaging. Feb 12 2024;24(1):26. doi: 10.1186/s40644-024-00670-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. May 1 1997;38(2):285–9. doi: 10.1016/s0360-3016(97)00101-6 [DOI] [PubMed] [Google Scholar]
  • 18.Kroenke M, Hirata K, Gafita A, et al. Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer. PLoS One. 2019;14(2):e0213111. doi: 10.1371/journal.pone.0213111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Yamada T, Uchida M, Kwang-Lee K, et al. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol. Apr 2012;113(4):464–71. doi: 10.1016/j.tripleo.2011.04.006 [DOI] [PubMed] [Google Scholar]
  • 20.Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. Feb 12 2002;86(4):512–6. doi: 10.1038/sj.bjc.6600114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Machtay M, Natwa M, Andrel J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck. Feb 2009;31(2):195–201. doi: 10.1002/hed.20942 [DOI] [PubMed] [Google Scholar]
  • 22.Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. Mar 1 2002;20(5):1398–404. doi: 10.1200/JCO.2002.20.5.1398 [DOI] [PubMed] [Google Scholar]
  • 23.Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. Feb 2002;24(2):127–35. doi: 10.1002/hed.10037 [DOI] [PubMed] [Google Scholar]
  • 24.Malone JP, Gerberi MA, Vasireddy S, et al. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography. Arch Otolaryngol Head Neck Surg. Nov 2009;135(11):1119–25. doi: 10.1001/archoto.2009.152 [DOI] [PubMed] [Google Scholar]
  • 25.Krabbe CA, Pruim J, Dijkstra PU, et al. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med. Dec 2009;50(12):1940–7. doi: 10.2967/jnumed.109.065300 [DOI] [PubMed] [Google Scholar]
  • 26.Zhong J, Sundersingh M, Dyker K, et al. Post-treatment FDG PET-CT in head and neck carcinoma: comparative analysis of 4 qualitative interpretative criteria in a large patient cohort. Sci Rep-Uk. Mar 5 2020;10(1)doi:ARTN 4086 10.1038/s41598-020-60739-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Greven KM, Williams DW, 3rd, , McGuirt WF Sr., et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. Nov 2001;23(11):942–6. doi: 10.1002/hed.1136 [DOI] [PubMed] [Google Scholar]
  • 28.Vernon MR, Maheshwari M, Schultz CJ, et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys. Mar 1 2008;70(3):678–84. doi: 10.1016/j.ijrobp.2007.10.044 [DOI] [PubMed] [Google Scholar]
  • 29.Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. Jun 3 2014;5:4006. doi: 10.1038/ncomms5006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Ferris RL, Blumenschein G, Jr., , Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. Nov 10 2016;375(19):1856–1867. doi: 10.1056/NEJMoa1602252 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Pota M, Scalco E, Sanguineti G, et al. Early prediction of radiotherapy-induced parotid shrinkage and toxicity based on CT radiomics and fuzzy classification. Artif Intell Med. Sep 2017;81:41–53. doi: 10.1016/j.artmed.2017.03.004 [DOI] [PubMed] [Google Scholar]
  • 32.Bogowicz M, Leijenaar RTH, Tanadini-Lang S, et al. Post-radiochemotherapy PET radiomics in head and neck cancer - The influence of radiomics implementation on the reproducibility of local control tumor models. Radiother Oncol. Dec 2017;125(3):385–391. doi: 10.1016/j.radonc.2017.10.023 [DOI] [PubMed] [Google Scholar]
  • 33.Folkert MR, Setton J, Apte AP, et al. Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics. Phys Med Biol. Jul 7 2017;62(13):5327–5343. doi: 10.1088/1361-6560/aa73cc [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Vallieres M, Kay-Rivest E, Perrin LJ, et al. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci Rep. Aug 31 2017;7(1):10117. doi: 10.1038/s41598-017-10371-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ger RB, Zhou S, Elgohari B, et al. Radiomics features of the primary tumor fail to improve prediction of overall survival in large cohorts of CT- and PET-imaged head and neck cancer patients. PLoS One. 2019;14(9):e0222509. doi: 10.1371/journal.pone.0222509 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ji H, Lafata K, Mowery Y, et al. Post-Radiotherapy PET Image Outcome Prediction by Deep Learning Under Biological Model Guidance: A Feasibility Study of Oropharyngeal Cancer Application. Front Oncol. 2022;12:895544. doi: 10.3389/fonc.2022.895544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lafata KJZ Z; Liu JG; Yin FF Data clustering based on Langevin annealing with a self-consistent potential. Quart Appl Math. 2019;77:591–613. doi: 10.1090/qam/1521 [DOI] [Google Scholar]
  • 38.Stevens JB, Riley BA, Je J, et al. Radiomics on spatial-temporal manifolds via Fokker-Planck dynamics. Med Phys. May 2024;51(5):3334–3347. doi: 10.1002/mp.16905 [DOI] [PubMed] [Google Scholar]
  • 39.Wang C, Liu C, Chang Y, et al. Dose-Distribution-Driven PET Image-Based Outcome Prediction (DDD-PIOP): A Deep Learning Study for Oropharyngeal Cancer IMRT Application. Front Oncol. 2020;10:1592. doi: 10.3389/fonc.2020.01592 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Cherezov D, Goldgof D, Hall L, et al. Revealing Tumor Habitats from Texture Heterogeneity Analysis for Classification of Lung Cancer Malignancy and Aggressiveness. Sci Rep-Uk. Mar 14 2019;9 doi:ARTN 4500 10.1038/s41598-019-38831-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Jeong SY, Park JE, Kim N, Kim HS. Hypovascular Cellular Tumor in Primary Central Nervous System Lymphoma is Associated with Treatment Resistance: Tumor Habitat Analysis Using Physiologic MRI. Am J Neuroradiol. Jan 2022;43(1):40–47. doi: 10.3174/ajnr.A7351 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Kazerouni AS, Hormuth DA 2nd, Davis T, et al. Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer. Cancers (Basel). Apr 6 2022;14(7)doi: 10.3390/cancers14071837 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Lee DH, Park JE, Kim HS. Tumor Habitat Analysis by Magnetic Resonance Imaging Distinguishes Tumor Progression from Radiation Necrosis in Brain Metastases after Stereotactic Radiosurgery. Neuro-Oncology. Nov 2021;23:127–127. [DOI] [PubMed] [Google Scholar]
  • 44.Lee DH, Park JE, Kim N, et al. Tumor Habitat Analysis Using Longitudinal Physiological MRI to Predict Tumor Recurrence After Stereotactic Radiosurgery for Brain Metastasis. Korean J Radiol. Mar 2023;24(3):235–246. doi: 10.3348/kjr.2022.0492 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Syed AK, Whisenant JG, Barnes SL, Sorace AG, Yankeelov TE. Multiparametric Analysis of Longitudinal Quantitative MRI Data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer. Cancers. Jun 2020;12(6)doi:ARTN 1682 10.3390/cancers12061682 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Zwanenburg A, Vallieres M, Abdalah MA, et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. May 2020;295(2):328–338. doi: 10.1148/radiol.2020191145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. Mar 2017;67(2):93–99. doi: 10.3322/caac.21388 [DOI] [PubMed] [Google Scholar]
  • 48.Stevens JB, Riley BA, Je J, et al. Radiomics on spatial-temporal manifolds via Fokker-Planck dynamics. Med Phys. Jan 8 2024;doi: 10.1002/mp.16905 [DOI] [PubMed] [Google Scholar]
  • 49.Gao Y, Liu JG, Wu N. Data-driven efficient solvers for Langevin dynamics on manifold in high dimensions. Appl Comput Harmon A. Jan 2023;62:261–309. doi: 10.1016/j.acha.2022.09.003 [DOI] [Google Scholar]
  • 50.Medved A, Davis R, Vasquez PA. Understanding Fluid Dynamics from Langevin and Fokker-Planck Equations. Fluids. Mar 2020;5(1)doi:ARTN 40 10.3390/fluids5010040 [DOI] [Google Scholar]
  • 51.Georgii H-O. Gibbs measures and phase transitions. De Gruyter studies in mathematics. W. de Gruyter; 1988:xiv, 525 p. [Google Scholar]
  • 52.Gao Y, Jin GZ, Liu JG. Inbetweening Auto-Animation Via Fokker-Planck Dynamics and Thresholding. Inverse Probl Imag. Oct 2021;15(5):843–864. doi: 10.3934/ipi.2021016 [DOI] [Google Scholar]
  • 53.Bezdek JC. Pattern recognition with fuzzy objective function algorithms. Advanced applications in pattern recognition. Plenum Press; 1981:xv, 256 p. [Google Scholar]
  • 54.Xie XLB G A validity measure for fuzzy clustering. IEEE Transactions on Pattern Analysis and Machine Intelligence. 1991;13(8):841–847. doi: 10.1109/34.85677 [DOI] [Google Scholar]
  • 55.Rousseeuw PJ. Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. Journal of Computational and Applied Mathematics. 1987;20:53–65. doi: 10.1016/0377-0427(87)90125-7 [DOI] [Google Scholar]
  • 56.Kaufman L, Rousseeuw PJ, ProQuest. Finding groups in data : an introduction to cluster analysis. Wiley series in probability and mathematical statistics Applied probability and statistics. Wiley; 1990. [Google Scholar]
  • 57.Chang Y, Lafata K, Wang C, et al. Digital phantoms for characterizing inconsistencies among radiomics extraction toolboxes. Biomed Phys Eng Express. Mar 2 2020;6(2):025016. doi: 10.1088/2057-1976/ab779c [DOI] [PubMed] [Google Scholar]
  • 58.Lafata KJ. Novel identification of radiomic biomarkers with Langevin annealing Duke University; 2018. [Google Scholar]
  • 59.Riley BA, Stevens JB, Li X, et al. Prognostic value of different discretization parameters in (18)fluorodeoxyglucose positron emission tomography radiomics of oropharyngeal squamous cell carcinoma. J Med Imaging (Bellingham). Mar 2024;11(2):024007. doi: 10.1117/1.JMI.11.2.024007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Roy S, Whitehead TD, Quirk JD, et al. Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging. EBioMedicine. Sep 2020;59:102963. doi: 10.1016/j.ebiom.2020.102963 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Lin P, Xie W, Li Y, et al. Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma. J Immunother Cancer. Nov 5 2024;12(11)doi: 10.1136/jitc-2024-009616 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer. Jul 21 2003;89(2):232–8. doi: 10.1038/sj.bjc.6601118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Creed J MatSurv: Survival analysis and visualization in MATLAB. J Open Source Software. 2020;5:1830. [Google Scholar]
  • 64.Xu T, Yuan Y, He C, Yang K. Construction and Evaluation of a Risk Score Model for Autophagy-Related Genes in Esophageal Adenocarcinoma. Med Sci Monit. Jan 29 2021;27:e927850. doi: 10.12659/MSM.927850 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Galloway MM. Texture analysis using gray level run lengths. Computer Graphics and Image Processing. 1975;4(2):172–179. doi: 10.1016/S0146-664X(75)80008-6. [DOI] [Google Scholar]
  • 66.Haralick RMS K; Dinstein I Textural features for image classification. IEEE Transactions on Systems, Man, and Cybernetics. 1973;3(6):610–621. doi: 10.1109/TSMC.1973.4309314. [DOI] [Google Scholar]
  • 67.Thibault GA J; Meyer F Advanced statistical matrices for texture characterization: application to cell classification. IEEE transactions on bio-medical engineering. 2014;61(3):630–637. doi: 10.1109/TBME.2013.2284600. [DOI] [PubMed] [Google Scholar]
  • 68.Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol. Aug 2006;80(2):151–6. doi: 10.1016/j.radonc.2006.07.033 [DOI] [PubMed] [Google Scholar]
  • 69.Bosque JJ, Calvo GF, Molina-Garcia D, Perez-Beteta J, Garcia Vicente AM, Perez-Garcia VM. Metabolic activity grows in human cancers pushed by phenotypic variability. iScience. Mar 17 2023;26(3):106118. doi: 10.1016/j.isci.2023.106118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Read GH, Bailleul J, Vlashi E, Kesarwala AH. Metabolic response to radiation therapy in cancer. Mol Carcinog. Feb 2022;61(2):200–224. doi: 10.1002/mc.23379 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Tang L, Wei F, Wu Y, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. Apr 23 2018;37(1):87. doi: 10.1186/s13046-018-0758-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. Oct 12 2010;103(8):1139–43. doi: 10.1038/sj.bjc.6605912 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. Dec 1 2012;72(23):6097–101. doi: 10.1158/0008-5472.CAN-12-3232 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Curtis SB. Lethal and potentially lethal lesions induced by radiation--a unified repair model. Radiat Res. May 1986;106(2):252–70. [PubMed] [Google Scholar]
  • 75.Wang Y, Li X, Konanur M, et al. Towards optimal deep fusion of imaging and clinical data via a model-based description of fusion quality. Med Phys. Jun 2023;50(6):3526–3537. doi: 10.1002/mp.16181 [DOI] [PubMed] [Google Scholar]
  • 76.Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med. Jan 6 2015;13:1. doi: 10.1186/s12916-014-0241-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Abraham A, Pedregosa F, Eickenberg M, et al. Machine learning for neuroimaging with scikit-learn. Front Neuroinform. 2014;8:14. doi: 10.3389/fninf.2014.00014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Parmar C, Grossmann P, Bussink J, Lambin P, Aerts H. Machine Learning methods for Quantitative Radiomic Biomarkers. Sci Rep. Aug 17 2015;5:13087. doi: 10.1038/srep13087 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Hou R, Lo JY, Marks JR, Hwang ES, Grimm LJ. Classification performance bias between training and test sets in a limited mammography dataset. PLoS One. 2024;19(2):e0282402. doi: 10.1371/journal.pone.0282402 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Chen Y, Yang Z, Zhao J, et al. A radiomics-incorporated deep ensemble learning model for multi-parametric MRI-based glioma segmentation. Phys Med Biol. Sep 13 2023;68(18)doi: 10.1088/1361-6560/acf10d [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental material

Data Availability Statement

Research data are stored in an institutional repository and deidentified data will be shared upon request to the corresponding author through a data use agreement.

RESOURCES